Paliperidone palmitate

Drug Profile

Paliperidone palmitate

Alternative Names: Invega Sustenna; Invega Trinza; Paliperidone palmitate long-acting injection; R0-92670; RO-92670; Sustenna; Trevicta; Xeplion

Latest Information Update: 16 Sep 2016

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen Pharmaceutical KK; Johnson & Johnson; Xian-Janssen
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 14 Sep 2016 Scottish Medicines Consortium (SMC) accepts paliperidone palmitate for the treatment of Schizophrenia (In adults)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in Croatia (IM, Controlled release)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in Israel (IM, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top